Actively Recruiting
PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)
Led by Rambam Health Care Campus · Updated on 2025-08-01
1084
Participants Needed
14
Research Sites
413 weeks
Total Duration
On this page
Sponsors
R
Rambam Health Care Campus
Lead Sponsor
R
Rabin Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
Data regarding optimal treatment for extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae blood-stream infection are lacking. Observational studies show conflicting results when comparing treatment with combination beta-lactam-beta-lactamase inhibitor and carbapenems. The investigators aim to evaluate the effect of definitive treatment with meropenem vs. piperacillin-tazobactam on the outcome of patients with bacteremia due to cephalosporin-non-susceptible Enterobacteriaceae. The investigators hypothesize that piperacillin-tazobactam is non-inferior to meropenem.
CONDITIONS
Official Title
PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- New onset bloodstream infection caused by E. coli or Klebsiella species confirmed in one or more blood cultures
- The bacteria must be resistant to third generation cephalosporins but susceptible to both piperacillin-tazobactam and meropenem
- Both community-acquired and hospital-acquired bloodstream infections are included
- Inclusion allowed if blood culture shows skin bacteria considered contaminants alongside E. coli or Klebsiella spp.
You will not qualify if you...
- More than 72 hours have passed since the initial blood culture was taken
- Polymicrobial bacteremia, defined as growth of two or more different microorganisms in the same or separate blood cultures during the same episode
- Previous bacteremia or infection without completed antibiotic treatment for that episode
- Septic shock at enrollment, defined by low blood pressure and/or use of certain vasopressors within 12 hours before enrollment
- Bloodstream infections due to endocarditis, osteomyelitis (unresected), or central nervous system infections
- Known allergy to piperacillin-tazobactam or meropenem
- Previous participation in this trial
- Concurrent participation in another interventional clinical trial
- Imminent death expected within 48 hours as assessed by the researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 14 locations
1
University of Calgary, Cumming School of Medicine, O'Brien Institute for Public Health
Calgary, Alberta, Canada, T2N 4Z6
Actively Recruiting
2
Surrey Memorial Hospital - Fraser Health Authority
Surrey, British Columbia, Canada
Actively Recruiting
3
Eastern Health
St. John's, Newfoundland and Labrador, Canada
Actively Recruiting
4
Kingston General Hospital
Kingston, Ontario, Canada
Actively Recruiting
5
Jewish Genral Hospital
Montreal, Quebec, Canada, H3T 1E2
Actively Recruiting
6
McGill University Health Centre
Montreal, Quebec, Canada
Actively Recruiting
7
Rambam Health Care Campus
Haifa, Israel, Israel, 3435306
Actively Recruiting
8
Soroka Medical Center
Beersheba, Israel
Actively Recruiting
9
Hadassah Medical Center
Jerusalem, Israel
Actively Recruiting
10
Meir Medical Center
Kfar Saba, Israel
Actively Recruiting
11
Sanz Medical Center-Laniado Hospital
Netanya, Israel, 42150
Actively Recruiting
12
Rabin Medical Center, Beilinson Campus
Petah Tikva, Israel
Actively Recruiting
13
Sheba Medical Center (Tel HaShomer)
Tel Aviv, Israel
Actively Recruiting
14
Sourasky Medical Center
Tel Aviv, Israel
Actively Recruiting
Research Team
M
Mical Paul, MD
CONTACT
R
Roni Bitterman, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here